GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's score of 82 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 645,000,000 kg CO2e for Scope 1 and 2, and significant Scope 3 emissions, which are not fully detailed. GSK has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2045, using 2020 as the base year. For near-term targets, GSK commits to an 80% reduction in absolute Scope 1 and 2 emissions by 2030, alongside a similar 80% reduction in Scope 3 emissions, which encompass areas such as purchased goods and services, business travel, and waste generated in operations. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by 2045. GSK's emissions data reflects a proactive approach to climate action, aligning with industry standards and the Science Based Targets initiative (SBTi). The company is also a signatory of the Amazon Climate Pledge, further demonstrating its commitment to sustainability and climate responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.